<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081349</url>
  </required_header>
  <id_info>
    <org_study_id>SKhaled2021</org_study_id>
    <nct_id>NCT05081349</nct_id>
  </id_info>
  <brief_title>Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia</brief_title>
  <official_title>Treatment With Hydoxycarbamide and L-Carnitine in Adult Patients With Severe Forms of Sickle Cell Anemia: An Overview</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of the combination therapy of hydroxyurea and L-Carnitine was studied in thalassemic&#xD;
      patients. nevertheless its role in sickle cell anemia patients was not investigated&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) is a common monogenic disorder affecting over 100,000 people in the&#xD;
      United States alone, and millions more worldwide. This often devastating disease is&#xD;
      characterized by red blood cell (RBC) sickling; chronic hemolytic anemia; episodic&#xD;
      vaso-occlusion associated with severe pain and inflammation; acute and cumulative organ&#xD;
      damage that manifests as stroke, acute chest syndrome, sickle lung disease, pulmonary&#xD;
      hypertension nephropathy and end-stage renal disease; and other chronic morbidities.&#xD;
&#xD;
      Lives of patients with SCD are characterized by frequent episodes of severe pain&#xD;
      (vaso-occlusive events or &quot;crises&quot;); acute organ dysfunction, including a pneumonia-like&#xD;
      syndrome termed acute chest syndrome, and strokes starting in childhood; and progressive&#xD;
      multi-organ damage. Not surprisingly, patients with SCD have very high health care&#xD;
      utilization (over $1 billion/year in healthcare costs in the United States alone, and a&#xD;
      median life-expectancy of only ~45-58 years, compared to the life expectancy of 78.2 years&#xD;
      overall in the United States.&#xD;
&#xD;
      Although it is licensed in the United States for administration to sickle cell patients who&#xD;
      have ≥ 3 crises a year in steady state, hydroxyurea (HU) remains unlicensed in most countries&#xD;
      where it is regarded as an experimental drug In those areas, where HU is unlicensed for SCD,&#xD;
      it is offered to patients who have ≥ 5 crises a year; or 3-4 crises a year with either&#xD;
      neutrophil count ≥ 10 × 109/L or platelet count ≥ 500 × 109/L in steady state ; bearing in&#xD;
      mind that the reference range for neutrophil count in black people is 1-3 × 109/L, and is&#xD;
      100-300 × 109/L for platelets .&#xD;
&#xD;
      Since high neutrophil count in steady state is a marker of severe SCD , these criteria&#xD;
      usually identify individuals who have a clinical course sufficiently severe to ensure that&#xD;
      the benefits of hydroxyurea therapy justify the potential risks. HU therapy is offered if the&#xD;
      patient does not want to have (more) children, and is weighed against any severe impairment&#xD;
      of liver or kidney function, or blood cytopenia. HU is unlicensed in most countries because&#xD;
      the long-term adverse effects are unknown, not because the clinical efficacy is in doubt. In&#xD;
      fact, after over 9 years of follow-up, HbSS subjects who received HU in the US&#xD;
      placebo-controlled trial, had significantly less painful crises, acute chest syndrome, and&#xD;
      mortality . Potential long-term toxic effects that reduce enthusiasm for HU include&#xD;
      teratogenicity, carcinogenesis and, for young children, impaired cognitive development.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Actual">July 10, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematological(HR)</measure>
    <time_frame>2-3 months</time_frame>
    <description>Change of hemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematological response</measure>
    <time_frame>2-3 months</time_frame>
    <description>Change of hematocrit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of painful episodes/ blood transfusions</measure>
    <time_frame>1-year</time_frame>
    <description>Change of frequency of painful episodes and blood transfusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Delayed effects</measure>
    <time_frame>12-18 months</time_frame>
    <description>effect on long term complications as cardiovascular and cerebrovascular ones</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Hydra+L-Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxycarbamide+ L-Carnitine+supportive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydra only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxycarbamide+ supportive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Carnitine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-Carnitine+ supportive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supportive measures</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Supportive only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Hydra+L-Carnitine</arm_group_label>
    <other_name>Hydroxyurea+LC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide 500 Mg Oral Capsule</intervention_name>
    <description>Single agent</description>
    <arm_group_label>Hydra only</arm_group_label>
    <other_name>Hydroxyurea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Carnitine, 250 Mg Oral Capsule</intervention_name>
    <description>single agent</description>
    <arm_group_label>L-Carnitine only</arm_group_label>
    <other_name>L-Carnitine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with sickle cell disease&#xD;
&#xD;
          -  Not welling for pregnancy in females or to father a baby in males&#xD;
&#xD;
          -  Frequent episodes&#xD;
&#xD;
          -  Non-compliance to transfusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Hypersensitivity to hydroxycarbamide or L-Carnitine&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Other chronic infection or inflammation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Israa EM Ashry, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University- Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Safaa A A Khaled</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997 Sep 11;337(11):762-9. Review.</citation>
    <PMID>9287233</PMID>
  </reference>
  <reference>
    <citation>Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31. doi: 10.1016/S0140-6736(10)61029-X. Epub 2010 Dec 3. Review.</citation>
    <PMID>21131035</PMID>
  </reference>
  <reference>
    <citation>Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44.</citation>
    <PMID>7993409</PMID>
  </reference>
  <reference>
    <citation>Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009 Jun;84(6):323-7. doi: 10.1002/ajh.21408.</citation>
    <PMID>19358302</PMID>
  </reference>
  <reference>
    <citation>Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014 May;89(5):530-5. doi: 10.1002/ajh.23683. Epub 2014 Feb 21.</citation>
    <PMID>24478166</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Safaa AA Khaled</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

